Table 1 Sections and topics of survey
From: Real-life experiences with galcanezumab and predictors for treatment response in Turkey
Section | Questions | Topics |
|---|---|---|
Demographics | 1–6, 13 | Identity, age, gender, education, work status, physician |
Comorbidities | 8,9 | Comorbid diseases and treatment |
Clinical features of migraine | 10,11 | Type*, duration |
Previous migraine treatment | 12 | Past preventive treatment/s, |
Provider of galcanezumab | 7 | Reimbursement method |
Information about Galcanezumab treatment | 14,15,16,17, 20,21,22 | Continuing and/or quitting of treatment, a number of injections, a last date of injection, a duration of treatment, a length of treatment, |
Headache improvements with galcanezumab treatment | 18,19, 30, 32, 36,37 | A general thought about galcanezumab (beneficial or not), changes of headache frequency and severity, and frequency of acute medication use, MHDs, acute medication use in the past month |
Side effects | 23,24 | Adverse effect/s |
Previous clinical status of migraine | 25,26,27, 28, 29 | Pre-treatment MHDs, pain severity, acute medication use per month, classes of acute medication** |
Patient- reported primary outcomes | 31, 33, 35 | Change rates (0-100 scale) of headache frequency, severity, acute medication use |
Accompanying symptoms | 38, 39, 40 | Accompanying symptoms during migraine attacks and improvement rates in those symptoms, MBS |
Interictal burden | 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 | Mood, life quality, health, sleep, anxiety, control of migraine, sense of helpless, social or leisure activities, interpersonal relationships, attention, and concentration |